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Prophylactic Topical Tranexamic Acid Versus Placebo in
Surgical Patients
A Systematic Review and Meta-Analysis
Wan Yi Teoh, MBChB, Tun Giap Tan, BMBS,y Ka Ting Ng, MBChB,zY Ke Xin Ong,§
Xue Lin Chan, MBChB,z Samuel Ern Hung Tsan, BMBS,
and Chew Yin Wang, MBChB, FRCA, FFARCSz
Objectives: Perioperative bleeding remains a major concern to all clinicians
caring for perioperative patients. Due to the theoretical risk of thromboem-
bolic events associated with tranexamic acid (TXA) when administered
intravenously, topical route of TXA has been extensively studied, but its
safety and efficacy profile remain unclear in the literature. The primary aim of
this review was to assess the effect of topical TXA on incidence of blood
transfusion and mortality in adults undergoing surgery.
Data sources: EMBASE, MEDLINE, CENTRAL, and ISI Web of Science
were systematically searched from their inception until May 31, 2019.
Review methods: Parallel-arm randomized controlled trials were included.
Results: Seventy-one trials (7539 participants: orthopedics 5450 vs non-
orthopedics 1909) were included for quantitative meta-analysis. In compari-
son to placebo, topical TXA significantly reduced intraoperative blood loss
[mean difference (MD) 36.83 mL, 95% confidence interval (CI) 54.77 to
18.88, P < 0.001], total blood loss (MD 319.55 mL, 95% CI 387.42 to
251.69, P < 0.001), and incidence of blood transfusion [odds ratio (OR)
0.30, 95% CI 0.26–0.34, P< 0.001]. Patients who received topical TXAwere
associated with a shorter length of hospital stay (MD 0.28 days, 95% CI
0.47 to 0.08, P ¼ 0.006). No adverse events associated with the use of
topical TXAwere observed, namely mortality (OR 0.78, 95% CI 0.45–1.36, P
¼ 0.39), pulmonary embolism (OR 0.73, 95% CI 0.27–1.93, P ¼ 0.52), deep
vein thrombosis (OR 1.07, 95% CI 0.65–1.77, P ¼ 0.79), myocardial
infarction (OR 0.79, 95% CI 0.21–2.99, P ¼ 0.73), and stroke (OR 0.85,
95% CI 0.28–2.57, P ¼ 0.77). Of all included studies, the risk of bias
assessment was ‘‘low’’ for 20 studies, ‘‘unclear’’ for 26 studies and ‘‘high’’ for
25 studies.
Conclusions: In the meta-analysis of 71 trials (7539 patients), topical TXA
reduced the incidence of blood transfusion without any notable adverse events
associated with TXA in adults undergoing surgery.
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P atients undergoing major surgery are prone to substantial intra-operative and postoperative blood loss.1–4 Although allogenic
blood transfusion is a life-saving measure, it may lead to serious
adverse events, namely hemolytic transfusion reaction, transfusion-
related acute lung injury, and transmission of viral or bacterial
infections.5,6 All these adverse events could prolong the duration
of hospital stay, increase cost of hospitalisation, reduce quality of
life, and, at worst, may increase the risk of mortality.7
Many alternative strategies are available to reduce blood loss
perioperatively, namely use of tourniquet,8 hypotensive anesthesia,9
fibrin sealant,10 and topical pharmacological agents.11 Of these,
prophylactic administration of tranexamic acid (TXA) before or
during the major surgery is believed to reduce blood loss and
incidence of blood transfusion. TXA is an anti-fibrinolytic agent
approved for preventing or treating bleeding in different clinical
settings. It is a highly efficacious synthetic amino acid lysine
analogue,12,13 and is deemed as a cost-effective drug.14 TXA com-
petitively binds to the lysine-binding site of plasminogen to inhibit
the activation of plasminogen to plasmin and prevent the degradation
of fibrin clot, resulting in delaying fibrinolysis, enhancing hemostasis
and reducing blood loss.12,13 Given its anti-fibrinolytic mechanism of
action, thrombotic complications are a potential risk.
In light of the safety concern regarding the theoretical risk of
fatal thromboembolic event with intravenous administration of
TXA,15 topical route of TXA has been proposed as an alternative
measure to minimize blood loss. The plasma concentration of topical
TXA was found to be 90% lower than intravenous TXA.16 However,
topical TXA has been shown to result in a higher therapeutic
concentration at the bleeding site with minimal or no systemic
absorption.16,17 Many recent trials investigating the benefits of
topical TXA in surgery have been published with conflicting
results.18–23 Consequently, the efficacy and safety profile of topical
TXA remains unclear in the literature. A systematic review and meta-
analysis are timely warranted to synthesize current evidence on the
prophylactic use of TXA in adults undergoing surgery.
The primary aim of this systematic review and meta-analysis
was to evaluate the effects of topical TXA on incidence of blood
transfusion and mortality in adults undergoing surgery. Secondary
aims were to investigate the clinical effects of TXA on bleeding
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